cs pharmafilt watch
bottom line follow busi start year domin larg deal
lly/loxo even larger one bmy/celg continu nois around
us drug price potenti impact partial us govern
shutdown biopharma compani approach earn
kick us next week tuesday thursday
friday recent investor convers compani
domin specif topic talc litig risk
celg deal humira biosimilar risk although
also expect usual attent earn uptak new
product potenti upsid pipelin driver note present
updat model compani base analysi latest
prescript price trend appear best posit three
deliv quarterli beat although focu compani
detail guidanc maintain rate target
price three compani head earn
eastern releas call dial-in
yet recov sharp mid-decemb sell-off increas
concern around compani talc powder liabil risk compani
alreadi defend aggress wonder issu
address earn call also expect close scrutini
compani outlook follow sever year strong growth
remain confid outlook pharma busi driven stelara
imbruvica darzalex xarelto tremfya well potenti
approv esketamin erdafitnib look greater visibl
abil turn around medic devic consum segment
notabl rais stelara xarelto remicad estim
head result modestli lower simponi
releas call dial-in passcod
focu call certainli remain around bmi acquisit
celg investor question remain around merit deal
view celg base busi notabl revlimid mid-
late stage pipelin fundament level expect solid result
mostli driven opdivo cs estim global sale vs
consensu eliqui cs estim global sale
in-lin consensu increas eliqui orencia
estim head result lower yervoy estim
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
eastern releas call dial-in
under-perform rate primarili due
concern longev compani flagship product humira
expect compani initi perspect entri biosimilar
version humira europ impact outlook
key topic discuss call addit updat key pipelin
product upadacitinib risankizumab close watch
capit
deploy busi develop prioriti quarter
expect rel strong perform base volum growth
see us key product humira imbruvica
mavyret estim global humira sale slightli
consensu
compani may provid
pressur us major pharma compani provid guidanc
yoy chang trade weight dollar index major currenc index
board governor feder reserv system us trade weight dollar index major currenc dtwexm retriev fred feder reserv bank st loui
trade weight major currenc index base exchang rate us dollar basket major currenc includ euro area canada japan unit kingdom
switzerland australia sweden
charl martineau univers toronto figur currenc revers cours estim fx headwind
yoy chang trade weight dollar index major currenc index
chang
figur sequenti usd expect modestli stronger qoq current fx level
qoq chang trade weight dollar index major currenc index
chang
watch
passcod sale cs
ep cs
under-perform rate primarili due concern longev
compani flagship product humira expect compani initi
perspect entri biosimilar version humira europ
impact outlook key topic discuss
call addit updat key pipelin product upadacitinib
risankizumab close watch addit commentari
compani may provid capit deploy busi develop
prioriti quarter expect rel strong perform
base volum growth see us key product
humira imbruvica mavyret revis ep
estim move main
upsid risk call stronger-than-expect humira growth
longev unexpect pipelin success value-cr strateg move
manag team
notabl model updat rais humira sale
consensu imbruvica sale consensu
mavyret sale consensu
also increas creon sale quarter given continu
earn look commentari impact
biosimilar humira competit europ updat progress key
pipelin product upadacitinib risankizumab ahead potenti regulatori
approv decis later year updat compani capit
deploy busi develop prioriti work
diversifi busi away humira
valuat metric
number share
price month
 close
figur cs estim metric
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
 close
watch
passcod sale cs
ep cs focu call
certainli remain around bmi acquisit celg investor question
remain around merit deal view celg base
busi notabl revlimid mid-lat stage pipelin
fundament level expect solid result mostli driven opdivo
eliqui
revis ep estim
risk call
includ better worse-than-expect adopt opdivo better worse-
than-expect pipelin data potenti acquisit
target given discount multipl compar peer
notabl model updat maintain opdivo sale
forecast vs lower yervoy sale
forecast vs increas eliqui
sale estim con orencia forecast
vs
earn look increas commentari
insight decis acquir celg expect
celg base busi key mid-lat stage pipelin asset
commerci perform opdivo /- yervoy uptak face greater
competit keytruda updat expect around
upcom data part overal surviv data opdivo
yervoy vs chemotherapi patient part overal surviv
opdivo chemo vs chemo alon all-com
valuat metric
number share
price month
 close
figur cs estim metric
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
watch
sale cs
ep cs yet recov sharp mid-
decemb sell-off increas concern around compani talc powder
liabil risk compani alreadi defend aggress
wonder issu address earn call also expect
close scrutini compani outlook follow sever year
strong growth remain confid outlook pharma busi
driven stelara imbruvica darzalex xarelto tremfya well
potenti approv esketamin erdafitnib look greater
visibl abil turn around medic devic consum
success key competitor
imbruvica
esketamin biggest risk call
darzalex
notabl model updat notabl increas global sale
estim stelara vs consensu xarelto
vs consensu remicad vs
consensu modestli lower simponi vs
consensu
earn look commentari compani
see futur growth key driver xarelto darzalex imbruvica come
given recent data releas competit dynam market
clariti around possibl fda advisori committe meet
pdufa date esketamin compani updat capit alloc
busi develop prioriti updat on-going talc litig
valuat metric
number share
price month
 close
charl martineau univers toronto figur cs estim metric
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
good sold
total expens incom
incom tax basi
ep continu op
dilut ep oper
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
product sold ex-amort
tax earn
average share outstand
dilut ep oper
compani mention price
